A transient benign lymph node-based proliferation of T-cells simulating non-Hodgkin lymphoma in a patient with psoriasis treated with tumor necrosis factor alpha and CD11a antagoni...

por Hurley, M Yadira, George, Mary Noel, Leonardi, Craig L, Frater, John L
Publicado 2008

Wolf’s isotopic response of lichen planus following contact dermatitis

por Pollard, Bruin, McCoy, William H., Leonardi, Craig L., Martin, Ann G.
Publicado 2022

Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe Psoriasis

por Grace, Elsie, Goldblum, Orin, Renda, Lisa, Agada, Noah, See, Kyoungah, Leonardi, Craig, Menter, Alan
Publicado 2019

Three‐year U.S. pharmacovigilance report of brodalumab

por Lebwohl, Mark, Leonardi, Craig, Armstrong, April, Rawnsley, Nicole, Alexander, Binu, Goehring, Earl, Kerdel, Francisco, Jacobson, Abby
Publicado 2021

Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series

por Lowes, Michelle A, Chamian, Francesca, Abello, Maria V, Leonardi, Craig, Dummer, Wolfgang, Papp, Kim, Krueger, James G
Publicado 2007

Two-Year US Pharmacovigilance Report on Brodalumab

por Lebwohl, Mark, Leonardi, Craig, Wu, Jashin J., Armstrong, April, Rawnsley, Nicole, Merchant, Mohammed, Alexander, Binu, Jacobson, Abby
Publicado 2020

Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study

por Paul, Carle, Leonardi, Craig, Menter, Alan, Reich, Kristian, Gold, Linda Stein, Warren, Richard B., Møller, Anders, Lebwohl, Mark
Publicado 2017

Psoriasis Severity Assessment Combining Physician and Patient Reported Outcomes: The Optimal Psoriasis Assessment Tool

por Leonardi, Craig, See, Kyoungah, Gallo, Gaia, McKean-Matthews, Missy, Zhang, Ying, Goldblum, Orin, Mallbris, Lotus, Burge, Russel
Publicado 2021

Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis

por Leonardi, Craig L., See, Kyoungah, Burge, Russel, Sun, Zhuoer, Zhang, Ying, Mallbris, Lotus, Garrelts, Alyssa, Warren, Richard B.
Publicado 2022

Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis

por Ryan, Caitriona, Sobell, Jeffrey M., Leonardi, Craig L., Lynde, Charles W., Karunaratne, Mahinda, Valdecantos, Wendell C., Hendrickson, Barbara A.
Publicado 2018

Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis

por Hawkes, Jason E., See, Kyoungah, Burge, Russel, Strakbein, Stephanie, McKean-Matthews, Missy, Saure, Daniel, Gooderham, Melinda, Leonardi, Craig
Publicado 2021

Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Ph...

por Blauvelt, Andrew, Leonardi, Craig L., Gaylis, Norman, Jauch-Lembach, Julia, Balfour, Alison, Lemke, Lena, Hachaichi, Sohaib, Brueckmann, Ines, Festini, Teodora, Wiland, Piotr
Publicado 2021

Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan(®) Databases

por Leonardi, Craig, Zhu, Baojin, Malatestinic, William N., Eastman, William J., Guo, Jiaying, Murage, Mwangi J., Choong, Casey Kar-Chan, Burge, Russel, Blauvelt, Andrew
Publicado 2022

34346 Pooled safety analysis of respiratory tract infections, including COVID-19, in psoriasis patients treated with secukinumab

por Schulze-Koops, Hendrik, Deodhar, Atul, Voll, Reinhard E., Leipe, Jan, Blauvelt, Andrew, Leonardi, Craig, Pournara, Effie, Alarcon, Ivette, Bao, Weibin, Trivedi, Vivek, Mease, Philip J.
Publicado 2022

Clinical Symptoms of Skin, Nails, and Joints Manifest Independently in Patients with Concomitant Psoriasis and Psoriatic Arthritis

por Wittkowski, Knut M., Leonardi, Craig, Gottlieb, Alice, Menter, Alan, Krueger, Gerald G., Tebbey, Paul W., Belasco, Jennifer, Soltani-Arabshahi, Razieh, Gray, John, Horn, Liz, Krueger, James G.
Publicado 2011

Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis

por Armstrong, April, Fahrbach, Kyle, Leonardi, Craig, Augustin, Matthias, Neupane, Binod, Kazmierska, Paulina, Betts, Marissa, Freitag, Andreas, Kiri, Sandeep, Taieb, Vanessa, Slim, Mahmoud, Gomez, Natalie Nunez, Warren, Richard B.
Publicado 2022

A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis

por Krueger, James G., Suárez-Fariñas, Mayte, Cueto, Inna, Khacherian, Artemis, Matheson, Robert, Parish, Lawrence C., Leonardi, Craig, Shortino, Denise, Gupta, Akanksha, Haddad, Jonathan, Vlasuk, George P., Jacobson, Eric W.
Publicado 2015

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial

por Blauvelt, Andrew, Leonardi, Craig L., Gooderham, Melinda, Papp, Kim A., Philipp, Sandra, Wu, Jashin J., Igarashi, Atsuyuki, Flack, Mary, Geng, Ziqian, Wu, Tianshuang, Camez, Anne, Williams, David, Langley, Richard G.
Publicado 2020

Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR

por Bissonnette, Robert, Gottlieb, Alice B., Langley, Richard G., Leonardi, Craig L., Papp, Kim A., Pariser, David M., Uy, Jonathan, Lafferty, Kim Parnell, Langholff, Wayne, Fakharzadeh, Steven, Berlin, Jesse A., Brouwer, Emily S., Greenspan, Andrew J., Strober, Bruce E.
Publicado 2021

A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1

por Strober, Bruce E., Clay Cather, Jennifer, Cohen, David, Crowley, Jeffrey J., Gordon, Kenneth B., Gottlieb, Alice B., Kavanaugh, Arthur F., Korman, Neil J., Krueger, Gerald G., Leonardi, Craig L., Schwartzman, Sergio, Sobell, Jeffrey M., Solomon, Gary E., Young, Melodie
Publicado 2012